|Bid||82.80 x 1300|
|Ask||97.00 x 800|
|Day's range||94.61 - 96.90|
|52-week range||51.05 - 135.59|
|PE ratio (TTM)||N/A|
|Earnings date||30 Jul 2018 - 3 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||107.07|
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
NEW YORK, June 07, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.
NEW YORK, May 18, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AG ...
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.
The New York-based company said it had a loss of $3.22 per share. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss ...
Intercept Pharmaceuticals, Inc. (ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced its financial results for the quarter ended March 31, 2018. “We are pleased with our progress to date in 2018, as we continue to work to strengthen our leadership position in NASH and remain on track for the top line readout of data from our Phase 3 REGENERATE trial in the first half of 2019. Based on our review of the evolving competitive landscape, the new data released at the recent International Liver Congress in Paris and the strength of OCA’s Phase 2 and other data, we continue to believe in OCA’s significant potential in NASH,” said Mark Pruzanski, M.D., President and Chief Executive Officer of Intercept.
NEW YORK, May 01, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
Amicus Therapeutics (FOLD) is a global patient-focused biotechnology company engaged in developing and commercializing diverse novel treatments for patients with rare metabolic diseases. As of April 2018, of the seven analysts covering Amicus Therapeutics, three have given the stock “strong buy” ratings, three have given it “buy” ratings, and one has given it a “hold” rating. The mean rating for the stock is 1.71 with a target price of $19.93, implying an upside of almost 45% to $13.79 as of its closing on April 24.
NEW YORK, April 24, 2018-- Intercept Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, ...
Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).
CymaBay launched to a month-high Wednesday after unveiling strong data for a liver disease treatment — to the detriment of Intercept which has struggled with its rival drug.
Intercept Pharmaceuticals (ICPT) spent $265.4 million on operating activities in fiscal 2017 compared with $342.4 million in fiscal 2016. In fiscal 2017, Intercept Pharmaceuticals generated $2.8 million from financing activities, which were mainly from the exercise of options to purchase common stock. On April 5, 2018, Intercept Pharmaceuticals announced pricing of the upsized $250 million public offering of its common stock with a concurrent private placement of 1.5 million of its common shares.
Enanta Pharmaceuticals (ENTA) is a biotechnology company with a chemistry-driven approach. Enanta Pharmaceuticals discovered glecaprevir, a protease inhibitor for the treatment of chronic hepatitis C virus (or HCV). Enanta’s second protease inhibitor under its collaboration with AbbVie is marketed under the tradename Viekera Pak under AbbVie’s initial DAA regimens for the treatment of chronic HCV.
Acorda Therapeutics (ACOR), a biopharmaceutical company, develops therapies for neurological disorders. Of the ten analysts covering Acorda Therapeutics in April 2018, three have recommended “buy,” six have recommended “hold,” and one has recommended “sell.” Their mean rating for the stock is 2.8, and their target price is $24.78. Of the 20 analysts covering Intercept Pharmaceuticals (ICPT) in April 2018, ten have recommended “buy” or a higher rating, seven have recommended “hold,” and three have recommended “sell.” The mean rating for the stock is 2.5, and its target price is $110.91.